This is the published version of a paper published in *OncoTarget*.

Citation for the original published paper (version of record):

Bagnato, P., Castagnino, A., Cortese, K., Bono, M., Grasso, S. et al. (2017) Cooperative but distinct early co-signaling events originate from ERBB2 and ERBB1 receptors upon trastuzumab treatment in breast cancer cells. *OncoTarget*, 8(36): 60109-60122
https://doi.org/10.18632/oncotarget.17686

Access to the published version may require subscription.

N.B. When citing this work, cite the original published paper.

Permanent link to this version:
http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-139807
Cooperative but distinct early co-signaling events originate from ERBB2 and ERBB1 receptors upon trastuzumab treatment in breast cancer cells

Paola Bagnato1,*, Alessia Castagnino1,*, Katia Cortese1,*, Maria Bono1, Silvia Grasso2, Grazia Bellese1, Tiziana Daniele3, Richard Lundmark4, Paola Defilippi2, Patrizio Castagnola5 and Carlo Tacchetti1,3

1DIMES, Dipartimento di Medicina Sperimentale, Anatomia Umana, Università di Genova, Genova, Italy
2Molecular Biotechnology Centre and Department of Genetics, Biology and Biochemistry, Torino, Italy
3San Raffaele Scientific Institute, Experimental Imaging Centre, Milan, Italy
4Department of Medical Biochemistry and Biophysics, Umea University, Umea, Sweden
5Department of Integrated Oncological Therapies, IRCCS AOU - San Martino - IST, Largo Rosanna Benzi, Genova, Italy
*These authors have contributed equally to this work

Correspondence to: Patrizio Castagnola, email: patrizio.castagnola@hsanmartino.it
Carlo Tacchetti, email: tacchetti.carlo@hsr.it

Keywords: ERBB2, trastuzumab, circular dorsal ruffles, ERBB1, breast cancer

Received: November 15, 2016 Accepted: April 03, 2017 Published: May 08, 2017

ABSTRACT

ERBB2 receptor belongs to the ERBB tyrosine kinase receptor family. At variance to the other family members, ERBB2 is a constitutively active orphan receptor. Upon ligand binding and activation, ERBB receptors form homo- or hetero-dimers with the other family members, including ERBB2, promoting an intracellular signaling cascade. ERBB2 is the preferred dimerization partner and ERBB2 heterodimers signaling is stronger and longer acting compared to heterodimers between other ERBB members. The specific contribution of ERBB2 in heterodimer signaling is still undefined.

Here we report the formation of circular dorsal ruffles (CDRs) upon treatment of the ERBB2-overexpressing breast cancer cell lines SK-BR-3 and ZR751 with Trastuzumab, a therapeutic humanized monoclonal antibody directed against ERBB2. We found that in SK-BR-3 cells Trastuzumab leads to surface redistribution of ERBB2 and ERBB1 in CDRs, and that the ERBB2-dependent ERK1/2 phosphorylation and ERBB1 expression are both required for CDR formation. In particular, in these cells CDR formation requires activation of both the protein regulator of actin polymerization N-WASP, mediated by ERK1/2, and of the actin depolymerizing protein cofilin, mediated by ERBB1. Furthermore, we suggest that this latter event may be inhibited by the negative cell motility regulator p140Cap, as we found that p140Cap overexpression led to cofilin deactivation and inhibition of CDR formation.

In conclusion, here we show for the first time an ERBB2-specific signaling contribution to an ERBB2/ERBB1 heterodimer, in the activation of a complex biological process such as the formation of CDRs.

INTRODUCTION

ERBB2 (Her2/Neu) is a member of the ERBB family of receptor tyrosine kinases (RTKs), which includes EGFR (ERBB1), ERBB3, and ERBB4. ERBB2 is an orphan receptor and is the preferred dimerization partner for ERBB1, 3, and 4, upon their activation following the binding to specific ligands, e.g. EGF, TGF-α, and amphiregulin (for EGFR), or Heregulins/Neuregulins (for ERBB3/4) [1–3]. The oncogenic signaling by ERBB2
ERBB2-overexpressing breast cancer cells, promotes with cancer metastasis [19], but their possible clinical transformed cells [19], CDR-related mesenchymal-like Despite cancer cells form less CDRs as compared to non actin cytoskeleton preparing for cell motility [19, 29]. inducer internalization of RTKs after ligand stimulation, conclusively clarified, it has been suggested that CDRs PM extension [28] might be implicated in CDR disassembly. CDR formation [19]. Moreover, cofilin, an actin-binding binding protein involved in polymerization of actin filaments dependent phosphorylation of cortactin [25, 26], an actin-s syndromes (WAS) family of proteins N-WASP and WA VE. a complex array of reactions, since actin polymerization is for several RTKs, ERBB1 included [19]. The formation of CDRs is, therefore, initiated by RTKs signaling and involves a complex array of reactions, since actin polymerization is induced by the Arp 2/3 activation by the Wiskott-Aldrich syndrome (WAS) family of proteins N-WASP and WAVE. Furthermore, activation of N-WASP is enhanced by ERK1/2-dependent phosphorylation of cortactin [25, 26], an actin-binding protein involved in polymerization of actin filaments necessary for the remodeling of actin cortical structures in CDR formation [19]. Moreover, cofilin, an actin-binding protein which disassembles actin filaments [27] and drives PM extension [28] might be implicated in CDR disassembly.

Although the functions of CDRs have not been conclusively clarified, it has been suggested that CDRs induce internalization of RTKs after ligand stimulation, macropinocytosis, and a rapid reorganization of the actin cytoskeleton preparing for cell motility [19, 29]. Despite cancer cells form less CDRs as compared to non transformed cells [19], CDR-related mesenchymal-like migration in 3-dimensional matrices has been associated with cancer metastasis [19], but their possible clinical relevance remains unclear.

In this study, we show that Tz treatment of the ERBB2-overexpressing breast cancer cells, promotes ERBB2/ERBB1 heterodimers and CDR formation. Taking advantage of this biological response, we identified and characterized two distinct and spatiotemporally coordinated ERBB2 and ERBB1 signaling pathways leading to CDR formation, thus dissecting the specific activity of ERBB2 in an ERBB2/ERBB1 heterodimer, in the absence of specific ERBB1 signaling.

RESULTS

Tz induces dramatic remodeling of the plasma membrane and circular dorsal ruffles formation

To characterize early events occurring at the level of the PM upon Tz binding to ERBB2, we analyzed the breast cancer cell line SK-BR-3, in a time range between 2 and 120 min of treatment with Tz. ERBB1 and Tz-bound ERBB2 distribution was revealed by immunofluorescence on fixed cells, using antibodies directed to human IgGs and ERBB1, respectively (Figure 1). While in untreated SK-BR-3 cells, ERBB2 and ERBB1 were mainly organized in clusters/patches at the cell periphery (Figure 1A), after 10 min of Tz the two receptors co-redistributed in bona fide CDRs (Figure 1B), and displayed a diffuse distribution on the PM after 120 min of treatment (Figure 1C). As expected, a diffuse co-redistribution of ERBB2 and ERBB1 on the PM was also observed upon EGF treatment after 20 min when the percentage of cells showing CDRs is negligible or absent (Supplementary Figure 1).

The co-localization in SK-BR-3 cells of ERBB2 with F-actin and with CDR markers such as cortactin and N-WASP:GFP chimera [34] confirmed that the observed structures were indeed CDRs (Figure 2A) as well as the colocalization of cortactin with F-actin and ERBB2 (Supplementary Figure 2). The percentage of cells displaying CDRs on their PM was also observed upon EGF treatment after 20 min when the percentage of cells showing CDRs was negligible or absent (Supplementary Figure 1).

To investigate whether in our system CDRs represent a PM domain responsible for ERBB2 endocytosis or a signaling platform, we first compared the internalization of this receptor with that of the transferrin receptor after transferrin binding by immunofluorescence...
analysis. Our results showed that ERBB2 internalization upon Alexa555-Tz administration is negligible compared to that occurring to the Alexa488-transferrin (Figure 3). Therefore, we hypothesized that ERBB2 redistribution at the cell surface and CDR induction may be more related to signaling events rather than endocytosis.

Indeed, CDR formation is a complex event involving a signaling-mediated actin remodeling. Tz is known to promote the phosphorylation of the ERBB2 kinase domain, and ERK1/2 activation in SK-BR-3 cells [12]. To assess the timing of these events in our experimental context, control untreated and Tz-treated SK-BR-3 cell lysates were processed for Tz IP and immunoblot analysis. We observed that ERBB2 Tyr1248 phosphorylation increased progressively from 2 to 120 min (Figure 4A), whereas ERK1/2 phosphorylation showed a peak after 2 min of Tz treatment (Figure 4B).

Since the ERK1/2 pathway is involved in actin nucleation, cytoskeleton reorganization [35], and activation of the cortactin-Arp2/3-N-WASP complex, involved in CDR formation [26], we tested whether the inhibition of the ERK1/2 activation would impair CDR formation induced by Tz. To this aim, we challenged the SK-BR-3 cells with the MEK1 specific inhibitor U0126, in combination with Tz, and scored the percentage of cells displaying CDRs. Under these conditions we detected a significantly lower fraction of cells displaying CDRs, after 10 min of treatment, compared to cells cultured in the absence of U0126 (Figure 4C). To assess whether ERBB2 interaction with N-WASP occurs after Tz treatment and depends from ERK1/2 activity, we performed co-IP studies in the absence and presence of U0126. The results revealed that the endogenous N-WASP co-immunoprecipitated with ERBB2 at 2 min (Figure 4D), whereas this association was lost after 20 min, suggesting that the molecular machinery for CDR formation was transiently assembled at earlier time points of Tz treatment and mostly disassembled at 20 min. Furthermore, we showed that the addition of U0126 impaired N-WASP co-IP with ERBB2 (Figure 4D). Overall, these results show that Tz-induced ERK1/2 signaling is necessary to promote CDR formation.

Figure 1: Trastuzumab (Tz) treatment modifies ERBB2 plasma membrane (PM) distribution and induces the formation of Circular Dorsal Ruffles (CDRs). SK-BR-3 control cells (NT) and SK-BR-3 cells treated with Tz at various time points, were fixed and immunostained for ERBB2 (green signal) and ERBB1 (red signal). Three different distribution patterns of PM ERBB2/ERBB1 were recognized (A, B, C). Arrowheads indicate peripheral patches (A); arrows indicate CDRs (B), while (C) shows diffuse membrane localization. Scale bars = 10 μm. (B) Cortical dorsal ruffles (CDRs) were observed after 10 and 15 min of Tz treatment.
ERBB1 is necessary for CDR formation induced by Tz

As immunofluorescence data showed a complete co-distribution of ERBB2 with ERBB1 in the CDRs, upon Tz treatment (Figure 1A), we decided to evaluate the specific contribution of the signaling downstream of either ERBB2 or ERBB1 in the CDR formation process.

To this end, we silenced ERBB1 in SK-BR-3 by RNA interference, using the ERBB1 siRNA #1 (SK-siERBB1) by RNA interference and observed a dramatic reduction of the percentage of cells displaying CDRs in the overall population of SK-siERBB1 compared to control SK-BR-3 cells (P<0.001) (Figure 5A). The impairment of CDR formation was even more evident when only those cells showing low expression or no expression at all of ERBB1 in the SK-siERBB1 cell population were taken into account (P<0.0001) (Figure 5A). Experiments performed using a different ERBB1 siRNA (ERBB1 siRNA #2) yielded similar results (Supplementary Figure 4) and we ruled out by immunofluorescence analysis that ERBB2 on the plasma membrane was lost in SK-siERBB1 cells (Supplementary Figure 5). These results suggested that ERBB1 promotes CDR induction by Tz.

Figure 2: Cortactin and N-WASP are recruited on Circular Dorsal Ruffles (CDRs) that are transient PM structures induced by Trastuzumab (Tz). (A) SK-BR-3 were treated with Tz for 15 minutes, fixed and processed for immunofluorescence. (a) F-Actin stained with fluorescent phalloidin; (b) Cortactin revealed with a specific antibody; (c) N-WASP:GFP chimera revealed in the green channel; (d, e, f) ERBB2 detected with anti-ERBB2 antibody. Arrowheads indicate colocalization of F-actin, cortactin and N-WASP:GFP green signals with ERBB2 red signals in CDRs (g, h, i). Scale bars = 10 μm. (B) Quantification of Tz-induced CDR formation in SK-BR-3 control cells (NT) and SK-BR-3 cells treated with Tz at various time points indicated in min. Bars represent the average ± SD of the data pooled from 3 independent experiments. At each time point at least 500 cells were analyzed.
As we observed a strong dependence of CDR formation on ERK1/2 signaling induced by Tz, we investigated whether the activation of this pathway depended on ERBB1. We found that SK-siERBB1 cells and those transfected with a control scrambled siRNA, displayed the same pattern of ERK1/2 activation upon Tz treatment (Figure 5B, 5C), which was also similar to that displayed by WT SK-BR-3 (Figure 4B). These data suggested that ERBB1 cooperates with ERBB2 in the Tz-induced CDR formation in an ERK1/2-independent manner, and that ERBB2 is likely the main activator of the ERK1/2 signaling under these conditions. Figure 5D shows the extent of the ERBB1 expression inhibition obtained in our experimental conditions.

**Overexpression of p140Cap recapitulates the inhibitory effect of ERBB1-depletion on CDR formation and induces inactivation of cofilin**

It has been previously shown that ERBB1 activity is antagonized by p140Cap protein [36], an adaptor protein involved in actin remodeling [32], which co-immunoprecipitates with ERBB1 [36]. In particular, p140Cap was described as an oncosuppressor acting as a negative regulator of cell motility and invasion [37], and ERBB2-mediated breast cancer progression [38]. To test the involvement of p140Cap in CDR formation induced by Tz, and its relationship with ERBB1 and ERBB2 signaling, we first evaluated the expression of p140Cap in WT SK-BR-3 and in SK-siERBB1 by immunoblot analysis of whole cell lysates. This analysis revealed that p140Cap was expressed at a lower level in WT SK-BR-3, compared to SK-siERBB1 (Supplementary Figure 6). Subsequently, we explored whether the p140Cap negative effect on CDR formation was due to its ability to induce cofilin phosphorylation as previously reported [39]. Indeed, by measuring the p-cofilin/cofilin ratio in p140Cap overexpressing SK-BR-3 cells (p140oe) and mock-transduced cells by immunoblot analysis, we found that p140Cap enhanced cofilin phosphorylation thus inhibiting its activity (P<0.01) (Figure 6A, 6B).

**Figure 3: Transferrin but not Tz induces receptor internalization within 120 min of treatment in SK-BR-3 cells.** SK-BR-3 cells were treated with Alexa555-conjugated Tz (red signal) and with Alexa488-conjugated transferrin (green signal), fixed and imaged by confocal microscopy at the indicate time points (upper left corner).
Figure 4: Trastuzumab (Tz) induces ERBB2 phosphorylation and activation of ERK 1/2 signaling which is necessary for N-WASP binding and CDRs formation. (A) Control SK-BR-3 (NT) or Tz treated at different time points as indicated (in min) were harvested and Tz bound ERBB2 was immunoprecipitated and blotted to analyze the extent of Tyr 1248 phosphorylation. (B) ERK1/2 phosphorylation (pERK1/2) levels were analyzed in total cell lysates and calnexin (CANX) was used as loading control. (C) SK-BR-3 were treated with Tz (white bars) or with Tz along with the MEK inhibitor U0126 (black bars) and cells displaying CDRs were scored at each indicated time point. Bars represent the average ± SD of the data pooled from 3 independent experiments. At each time point at least 500 cells were analyzed. (D) ERBB2 bound to Tz was immunoprecipitated and then endogenous N-WASP and ERBB2 were detected by western blot analysis in cells treated with Tz and/or with U0126 at various time points indicated in min.
Figure 5: ERBB1 is crucial for the CDR formation. SK-BR-3 wt or SK-BR-3 cells transfected with the siRNA #1 (see Material and Methods) specific for ERBB1 (SK-siERBB1) were treated with Tz for various times as indicated (in min). (A) Histogram of the percentage of cells showing CDRs at each time point. Bars represent the average ± SD of the percentage of cells with CDRs, observed at each time point pooled from 3 independent experiments. At each time point at least 500 cells were analyzed. The analysis was performed in either the total population of SK-BR-3 and SK-siERBB1 (tot) or only on those SK-siERBB1 cells showing very low or no ERBB1 signal (low). (B) Immunoblot analysis of ErbB1 expression and ERK1/2 phosphorylation (pERK1/2) in SK-siERBB1 cells. (C) Immunoblot analysis of ERBB1 expression and ERK1/2 signaling in SK-BR-3 cells transfected with a control siRNA (SK-control siRNA). (D) Immunoblot analysis of ERBB1 expression in SK-siERBB1 and SK-control siRNA. Calnexin (CANX) was used as loading control.
To understand whether p140Cap interacted with ERBB2 in both SK-BR-3 WT and SK-siERBB1 cells, we performed co-IP analysis of the Tz-bound ERBB2 and found an increased p140Cap-ERBB2 co-IP in SK-siERBB1, compared to SK-BR-3 WT cells (Figure 6C).

To evaluate the effect of p140Cap in CDR formation, we generated SK-BR-3 cell lines overexpressing the protein and the relative controls, SK-p140Cap overexpressing (SK-p140oe) and SK-mock transduced cells, respectively, and quantified the CDRs observed upon Tz treatment. These experiments showed a statistically significant reduction of the number of CDRs in SK-p140oe compared to SK-mock cells (P<0.05) after 15 min of treatment (Figure 6D). To establish whether the inhibitory effect of p140Cap on CDR formation was due to modulation of ERK1/2 signaling, we investigated by immunoblot analysis the levels of pERK1/2 and found no major differences between p140Cap-oe and mock transduced cells (Figure 7). In view of these results, we suggest that p140Cap may exert its negative activity on CDR formation independently from the ERK1/2 signaling pathway and possibly through coflin phosphorylation.

**ERBB1 promotes Tz-induced CDR formation by inhibiting coflin deactivation**

As p140Cap overexpression inhibits CDR formation and coflin activity by inducing its phosphorylation, we analyzed the phosphorylation status of coflin in both SK-siERBB1 and SK-BR-3 control cells transfected with a scrambled RNA oligonucleotide. The level of

---

**Figure 6: p140Cap co-immunoprecipitates with ERBB2, its overexpression recapitulates the inhibitory effect of ERBB1-depletion on CDRs formation and induces coflin phosphorylation.** (A) SK-p140oe and SK-mock whole cell lysates were analyzed for p140Cap expression levels, coflin phosphorylation (p-cofilin) and for total coflin. (B) Histogram showing the ratio of phosphorylated/total coflin as determined by immunoblot analysis in SK-mock and SK-p140oe cells. Bars represent the average ± SD of 3 independent experiments. (C) ERBB2 in SK-BR-3 wild type (SK-WT) and SK-siERBB1 was immunoprecipitated with Tz and ERBB2 and p140Cap were detected by immunoblot analysis. (D) Transduced SK-BR-3 cells overexpressing p140 (SK-p140oe) and SK-mock transduced cells were treated with Tz for various time points as indicated (in min) and the histogram showing the percentage of cells with CDRs at each time point. Histogram bars represent the average ± SD of the percentage of cells with CDRs, observed in 2 replicates. At each time point at least 500 cells were analyzed.
phosphorylated cofilin (p-cofilin) increases progressively during Tz treatment, in both silenced and control cells. However, p-cofilin reached significantly higher levels in SK-siERBB1, compared to SK-BR-3 cells (Figure 8), thus suggesting that ERBB1 signaling promoted cofilin activity by inhibiting its phosphorylation. Overall, these data suggest that upon Tz treatment of SK-BR-3 cells, ERBB1 negatively controls cofilin phosphorylation, thus promoting the actin filament severing and remodeling necessary to control CDR formation.

To test whether cofilin phosphorylation is sufficient to impair CDR formation, we expressed a phosphomimetic S3E mutant of cofilin SK-BR-3 cells, and scored the number of CDRs induced by Tz treatment, compared to cells transfected with WT cofilin, in three pooled independent experiments. The data showed a significant (P=0.02) reduction of CDR formation in SK-

![Whole cell lysates](image.png)

**Figure 7: p140Cap does not induce ERK1/2 phosphorylation.** Immunoblot analysis of ErbB2 expression and (pERK1/2) in SK-p140oe and SK-mock cell lysates. Calnexin (CANX) was used as loading control.

![Graph](image.png)

**Figure 8: ERBB1 depletion induces cofilin-1 phosphorylation, which inhibits CDRs formation.** (A) SK-BR-3 wild type (SK-WT) or SK-BR-3 cells transfected with siRNA specific for ERBB1 (SK-siERBB1) were untreated (NT) or treated with Tz for various time points as indicated (in min) and harvested for IP and western blot analysis. Whole cell lysates were analyzed for cofilin phosphorylation (p-cofilin) and total cofilin levels (cofilin). GAPDH was used as loading control. (B) SK-BR-3 cells were transfected with a construct expressing wt cofilin or the S3E cofilin mutant. Histogram bars represent the average ± SD of the percentage of cells with CDRs, observed in 3 replicates. For each experiment at least 3000 cells were analyzed.
BR-3 cells expressing the phosphomimetic S3E mutant (Figure 8B), compared to control cells. The expression of both coflin WT and of the phosphomimetic S3E mutant was assessed by immunofluorescence analysis (Supplementary Figure 7).

Taken together, our results show that Tz-induced formation of transient CDRs depends on the activation of ERK1/2 signaling triggered by ERBB2 and on ERBB1-mediated maintenance of coflin activity.

DISCUSSION

Trastuzumab is a humanized antibody directed against ERBB2 that revolutionized the treatment of ERBB2 breast cancers [10]. The introduction of Tz therapy and, more recently, of the first successful ERBB2-targeted antibody–drug conjugate (ADC), trastuzumab emtansine (T-DM1, Kadcyla, Genentech) markedly improved the poor prognosis associated with ERBB2-amplified breast cancers [40] [41] [42]. Notwithstanding, as the very early signaling events generated by Tz in targeted cells are poorly studied, we performed biochemical and morphological analyses in the ERBB2 overexpressing breast cancer cell line SK-BR-3 to determine the ERBB2 and ERBB1 signaling contribution in the context of an ERBB2/ERBB1 heterodimer. In particular, we observed that Tz induces CDR formation.

The formation of CDRs can be elicited by growth factors targeting RTKs [19]. Under these conditions, CDRs are proposed to act as spatially restricted signaling microdomains and as endocytic platform for receptor degradation [43]. Although CDRs significantly contribute to EGF-mediated ERBB1 internalization [37], here we observed poor ERBB2 internalization upon Tz-treatment as reported by others [17] [44]. These data support the hypothesis that Tz-induced CDRs may represent a transient but specific ERBB2/1 signaling platform in in vitro models. As little is known about the mechanism of their formation, it is important to determine the signaling pathways that are involved in Tz-induced CDR formation. N-WASP function, by binding to the RTK adaptor protein GRB2 [45], upstream of RAS-MEK mediated activation of ERK1/2, is critical for robust dorsal ruffles formation.

Here, we show for the first time that heterodimers formed by ERBB2/ERBB1 generates distinct signals, each necessary but not sufficient to induce the PM and cytoskeletal remodeling required for CDR formation. Firstly, we show that inhibition of the Tz dependent ERK1/2 phosphorylation via the MEK inhibitor U0126 impairs the N-WASP-ERBB2 interaction and the formation of CDRs. Because ERBB1 silencing is ineffective on ERK1/2 phosphorylation, we reason that this pathway only depends on the ERBB2 kinase activity. Secondly, we demonstrate that ERBB1 silencing completely abolished CDR formation, suggesting that a different ERBB1 signaling module is required for this process.

As actin-remodeling and the severing of pre-existing actin filaments are necessary for CDR formation, we concentrated our attention on a key protein that promotes these events, i.e coflin [46]. The actin-severing activity of coflin is inhibited by phosphorylation [47]. Indeed, we show that ERBB1 silencing increased the levels of p-cofilin, suggesting that the ERBB1 signaling module leading to CDR formation included maintenance of coflin in a dephosphorylated and active status. The role of the coflin/p-cofilin ratio in activating/inhibiting CDR formation upon Tz treatment was confirmed by the inhibition of CDR formation observed in cells overexpressing a coflin phosphomimetic mutant.

We also suggest that the link between ERBB1 signaling and coflin activity may be the p140Cap oncosuppressor protein. Indeed, SK-BR-3 cells overexpressing p140Cap display a lower percentage of cells with CDRs and an increased level of p-cofilin in the absence of changes of ERK1/2 phosphorylation levels compared to controls. Therefore, it appears that p140Cap has an inhibitory role on coflin activity, and eventually on the actin severing process necessary to CDR formation. As silencing of ERBB1 increases both the levels of p-cofilin and of p140Cap interaction with ERBB2, as demonstrated by co-IP assays, we suggest that upon Tz binding, the ERBB1 function in the ERBB2/ERBB1 heterodimer is to impair the p140Cap-mediated coflin inactivation, by displacing p140Cap from ERBB2.

In conclusion, the integration of these distinct signaling pathways is required to generate a specific crosstalk that is necessary to promote CDR formation. These data represent the first identification of an ERBB2 specific signaling activity in an ERBB heterodimer context.

MATERIALS AND METHODS

Cell culture and drug treatments

Breast cancer cell line SK-BR-3 and ZR751 were obtained from ATCC. SK-p140 and SK-mock transduced cell lines were developed by Dr. Paola Defilippi. Cells were cultured in DMEM, supplemented with 10% of fetal bovine serum, 1% glutamine and penicillin and streptomycin, at 37°C in a humidified atmosphere containing 5% CO₂.

Tz (Genentech-Roche, South San Francisco, CA, USA) was dissolved with saline solution with 0.9%NaCl in a stock concentration of 20 mg/ml, donated by the pharmacy (UFA-Unità Farmaci Antiblastici) of the IRCCS AOU - San Martino - IST. Where indicated, Tz was used conjugated with Alexa-488 using the Alexa Fluor 488 Protein Labeling Kit following the manufacturer's instructions (Molecular Probes, Eugene, OR, USA).
In all the experiments, Tz was used in a concentration of 10 μg/ml [30]. Cells were treated with Tz in DMEM serum-free at 37°C. When indicated cells were treated with 100 ng/ml EGF or 1 ng/ml transferrin.

In ERK1/2 inhibition experiments, cells were pre-incubated with 10μM U0126 (Promega, Madison, WI, USA), in DMEM serum-free at 37°C for 20 minutes, and maintained at the above concentration during the Tz treatment.

**Immunofluorescence analysis**

Cells were fixed in 3% paraformaldehyde (PFA) in phosphate-buffered saline (PBS) pH7.4 and then quenched with 30mM NH₄Cl. After permeabilization with 0.2% saponin/PBS, Tz (10 μg/ml) or mouse monoclonal anti-ERBB2 9G6 (sc-08, Santa Cruz, Santa Cruz, CA, USA) were used as primary antibody in cells followed by detection with an anti-human Cy2 and anti-mouse Cy2 or Cy3 antibodies, respectively.

The following primary antibodies were incubated for 20 min in 0.2% saponin/PBS: rabbit anti-cortactin (ab11066, Abcam, Cambridge, UK), mouse anti-ERBB1 (Ab 108, kindly provided by IFOM). The secondary antibodies were incubated for 20 min in 0.2% saponin/PBS: Cy3-conjugated donkey anti-mouse IgG (Jackson ImmunoResearch Laboratories, West Grove, PA, USA) and Alexa488-conjugated goat anti-human IgG (Molecular Probes). Where indicated, cells were treated with Tz conjugated with Alexa488 or Alexa555.

The F-actin staining was detected directly with 7μM Phalloidin-TRITC (P1951, Sigma-Aldrich, St. Louis, MO, USA) after cells fixation and permeabilization.

For nuclear staining, DAPI (Sigma) at 100 ng/ml was used for 5 min prior to mounting. The coverslips were mounted using Mowiol 4-88 reagent (Calbiochem, San Diego, CA, USA). Image acquisition was performed with an Olympus IX70 epifluorescence microscope. Images were captured under oil with a 63x plan apochromat objective. When indicated, images were acquired at 37°C with TCS-SP2 AOBs confocal microscope station (Leica Microsystems, Wetzlar, Germany).

**Immunoprecipitation (IP) and western blot analysis**

Protein cell extracts and SDS Polyacrylamide gel electrophoresis were performed using standard protocols [31]. Protein quantification was performed using Bradford protein assay (BioRad, Hercules, CA, USA). Tz administered to live starved cells (at 10μg/ml of final concentration) for 2 min or 20 min (serum free medium) was used as a primary anti-ERBB2 antibody. To immunoprecipitate ERBB2 from control Tz-untreated and starved cells we first performed cell lysis and subsequently added Tz to the cell lysate (at 10μg/ml of final concentration). Protein A-Sepharose CL-4B (GE Healthcare, Piscataway, NJ, USA) was added to the cell lysate to immunoprecipitate Tz bound to ERBB2. For ERBB1 IP, we used agarose-conjugated anti-EGFR (sc-03 AC, Santa Cruz Biotechnology, Santa Cruz, CA, USA).

Samples were separated by SDS-PAGE and analyzed by immunoblotting, using as primary antibodies: rabbit anti-ERBB2 (c-18, sc-284, Santa Cruz), rabbit anti p-ERBB2 Y1248 (#2247, Cell Signaling Technology, Danvers, MA, USA), goat anti-pERK1/2 (sc-16982, Santa Cruz), rabbit anti-calnexin (sc-11397, Santa Cruz), rabbit anti-GAPDH (#2118, Cell Signaling), mouse anti-cofilin (1G6A2, Proteintech, Rosemont, IL, USA), rabbit anti-p-cofilin (#3311, Cell Signaling), rabbit anti-cortactin (#3503, Cell Signaling), mouse anti-p140Cap (generated by Dr. Paola Defilippi’s laboratory) [32]. Secondary antibodies were horseradish peroxidase-conjugated: anti-mouse (Molecular Probes, Thermo Fisher Scientific, Waltham, MA, USA), anti-rabbit (Molecular Probes) and anti-goat (Santa Cruz) and the detection of proteins were performed with ECL Detection Reagent (GE Healthcare).

Densitometric analysis of western blots was performed with ImageJ Gel Analysis software.

**RNA interference**

SK-BR-3 cells were transiently transfected with two siRNA Stealth oligos (Invitrogen, Carlsbad, CA, USA) anti-ERBB1: #1 (5’-CCGCAGCAUGUCAAGAUCAC AGAUU-3’), and #2 (5’-CCACCGUGGCUUGCAUUG AUAGAAA-3’) using Lipofectamine 2000 accordingly to the manufacturer’s instructions (Invitrogen). All the experiments were performed using cells transfected with a scrambled (SCR) oligo as control (5’-CCGACGUGUAAC UAGCACGACAAUU-3’). Briefly, cells were subjected to two rounds of transfection, 24 and 48 hours after plating, and were treated and processed 72 hours after the first round of transfection.

**Transfection of expression vectors**

Construct transfections were performed using Lipofectamine 2000, accordingly to the manufacturer’s instructions (Invitrogen). Constructs employed in this study were: a N-WASP:GFP chimera [33] and the pmRFP-N1 human cofilin WT and S3E, which were acquired from Addgene (plasmid # 50856 and # 50858, Cambridge, MA, USA).

Localization of N-WASP:GFP in epifluorescent microscopy was performed 48h after cell transfection while CDRs were analyzed in cofilin WT:RFP and cofilin S3E:RFP chimera expressing cells 18h after transfection.
ERBB2 plasma membrane redistribution and Circular Dorsal ruffling assay and statistical analysis

To analyze the number of cells showing a single CDR two observers evaluated slides independently and at least 500 cells, for each experimental condition, were analyzed. All parameters measured are presented as mean ± standard deviation and were analyzed with the Student’s t-test using a two-tailed distribution. P values < 0.05 were considered statistically significant.

Abbreviations

Tz, Trastuzumab; RTKs, receptor tyrosine kinases; PM, plasma membrane; CDR, circular dorsal ruffle; IP, immunoprecipitation; GFP, green fluorescent protein.

Author contributions

Designed the project: CT. Conceived and designed the experiments: PB, AC, CT, PC, KC, PD, RL. Performed the experiments: PB, AC, KT, GB, TD, and SG. Analyzed the data: RL, PD, KC, PC, CT. Wrote the paper: KC, PC, CT.

ACKNOWLEDGMENTS

We thank Stefanie Benesch for the kind gift of pEGFP-N-WASP DNA construct.

CONFLICTS OF INTEREST

We confirm that there are no conflicts of interest associated with this publication and there has been no financial support for this work that could have influenced its outcome.

FUNDING

This study was supported by Compagnia San Paolo (grant number 2015.0323) and AIRC (IG12035) to Carlo Tacchetti.

REFERENCES

1. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005; 5:341–54.
2. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2:127–37.
3. Graus-Porta D, Beeeri RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J. 1997; 16:1647–55.
4. Akiyama T, Matsuda S, Namba Y, Saito T, Toyoshima K, Yamamoto T. The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl-terminal domain. Mol Cell Biol. 1991; 11:833–42.
5. Dittmar T, Husemann A, Schewe Y, Nofer JR, Niggemann B, Zänker KS, Brandt BH. Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR. FASEB J. 2002; 16:1823–25.
6. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Uldove J, Ullrich A, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244:707–12.
7. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235:177–82.
8. Brockhoff G, Heiss P, Schlegel J, Hofstaedter F, Kneucl R. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells. Cytometry. 2001; 44:338–48.
9. Graus-Porta D, Beeeri RR, Hynes NE. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol Cell Biol. 1995; 15:1182–91.
10. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 1992; 89:4285–89.
11. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr, Leahy DJ. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature. 2003; 421:756–60.
12. Dokmanovic M, Wu Y, Shen Y, Chen J, Hirsch DS, Wu WJ. Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition. Cancer Biol Ther. 2014; 15:1029–41.
13. Albanell J, Codony J, Rovira A, Mellado B, Gascón P. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol. 2003; 532:253–68.
14. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004; 6:117–27.
15. Valabrega G, Montemurro F, Saratto I, Petrelli A, Rubini P, Tacchetti C, Aglietta M, Comoglio PM, Giordano S. TGFlalpha expression impairs Trastuzumab-induced HER2 downregulation. Oncogene. 2005; 24:3002–10.
16. Klapper LN, Waterman H, Sela M, Yarden Y. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res. 2000; 60:3384–88.

17. Austin CD, De Mazière AM, Piscacane PI, van Dijk SM, Eigenbrot C, Sliwkowski MX, Klumperman J, Scheller RH. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and ganetanumab. Mol Biol Cell. 2004; 15:5268–82.

18. Longva KE, Pedersen NM, Haslekås C, Stang E, Madshus IH. Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int J Cancer. 2005; 116:359–67.

19. Hoon JL, Wong WK, Koh CG. Functions and regulation of circular dorsal ruffles. Mol Cell Biol. 2012; 32:4246–57.

20. Suetsugu S, Yamazaki D, Kurisu S, Takenawa T. Differential roles of WAVE1 and WAVE2 in dorsal and peripheral ruffle formation for fibroblast cell migration. Dev Cell. 2003; 5:595–609.

21. Chhabra ES, Higgs GN. The many faces of actin: matching assembly factors with cellular structures. Nat Cell Biol. 2007; 9:1110–21.

22. Dharmawardhane S, Sanders LC, Martin SS, Daniels RH, Bokoch GM. Localization of p21-activated kinase 1 (PAK1) to pinocytic vesicles and cortical actin structures in stimulated cells. J Cell Biol. 1997; 138:1265–78.

23. Hedberg KM, Bengtsson T, Safiecko-Mrocza B, Bell PB, Lindroth M. PDGF and neomycin induce similar changes in the actin cytoskeleton in human fibroblasts. Cell Motil Cytoskeleton. 1993; 24:139–49.

24. Bucciione R, Orth JD, McNiven MA. Foot and mouth: podosomes, invadopodia and circular dorsal ruffles. Nat Rev Mol Cell Biol. 2004; 5:647–57.

25. Kelley LC, Hayes KE, Ammer AG, Martin KH, Weed SA. Revisiting the ERK/Src cortactin switch. Commun Integr Biol. 2011; 4:205–07.

26. Martinez-Quiles N, Ho HY, Kirschner MW, Ramesh N, Geha RS. Erk/Src phosphorylation of cortactin acts as a switch on-switch off mechanism that controls its ability to activate N-WASP. Mol Cell Biol. 2004; 24:5269–80.

27. Ichetovkin I, Grant W, Condeelis J. Cofilin produces newly polymerized actin filaments that are preferred for dendritic nucleation by the Arp2/3 complex. Curr Biol. 2002; 12:79–84.

28. DesMarais V, Macaluso F, Condeelis J, Bailly M. Synergistic interaction between the Arp2/3 complex and cofilin drives stimulated lamellipod extension. J Cell Sci. 2004; 117:3499–510.

29. Mascia A, Gentile F, Izzo A, Mollo N, De Luca M, Bucci C, Nitsch L, Cali G. Rab7 regulates CDH1 Endocytosis, Circular Dorsal Ruffles Genesis and Thyroglobulin Internalization in a Thyroid Cell Line. J Cell Physiol. 2015.

30. Yeon CH, Pegram MD. Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer. Invest New Drugs. 2005; 23:391–409.

31. Harlow E, Lane DA. Using antibodies: a laboratory manual. Cold Spring Harbor (N.Y .): Cold Spring Harbor Laboratory Press; 2003.

32. Di Stefano P, Cabodi S, Boeri Erba E, Margaria V, Bergatto E, Giuffrida MG, Silengo L, Tarone G, Turco E, Defilippi P. P130Cas-associated protein (p140Cap) as a new tyrosine-phosphorylated protein involved in cell spreading. Mol Biol Cell. 2004; 15:787–800.

33. Benesch S, Polo S, Lai FP, Anderson KJ, Stradal TE, Wehland J, Rottner K. N-WASP deficiency impairs EGF internalization and actin assembly at clathrin-coated pits. J Cell Sci. 2005; 118:3103–15.

34. Itoh T, Hasegawa J. Mechanistic insights into the regulation of circular dorsal ruffle formation. J Biochem. 2013; 153:21–29.

35. Kelley LC, Hayes KE, Ammer AG, Martin KH, Weed SA. Cortactin phosphorylated by ERK1/2 localizes to sites of dynamic actin regulation and is required for carcinoma lamellipodia persistence. PLoS One. 2010; 5:e13847.

36. Damiano L, Le Dévéde SE, Di Stefano P, Repetto D, Dalai R, Truong H, Xiong JL, Danen EH, Yan K, Verbeek FJ, De Luca E, Attanasio F, Buccione R, et al. p140Cap suppresses the invasive properties of highly metastatic MTLn3-EGFR cells via impaired cortactin phosphorylation. Oncogene. 2012; 31:624–33.

37. Sharma N, Repetto D, Aramu S, Grasso S, Russo I, Fiorentino A, Mello-Grand M, Cabodi S, Singh V, Chiorino G, Turco E, Stefano PD, Defilippi P. Identification of two regions in the p140Cap adaptor protein that retain the ability to suppress tumor cell properties. Am J Cancer Res. 2013; 3:290–301.

38. Grasso S, Chapelle J, Salemme V, Aramu S, Russo I, Vitale N, Verdun di Cantogno L, Dallaglio K, Castellano I, Amici A, Centonze G, Sharma N, Lunardi S, et al. The scaffold protein p140Cap limits ERBB2-mediated breast cancer progression interfering with Rac GTPase-controlled circuitries. Nat Commun. 2017; 8:14797.

39. Repetto D, Camera P, Melani R, Morello N, Russo I, Calcagno E, Tomasoni R, Bianchi F, Berto G, Giustetto M, Berardi N, Pizzorusso T, Matteoli M, et al. p140Cap regulates memory and synaptic plasticity through Src-mediated and citron-N-mediated actin reorganization. J Neurosci. 2014; 34:1542–53.

40. Anampa J, Makower D, Sparano JA. Progress in adjuvant chemotherapy for breast cancer: an overview. BMC Med. 2015; 13:195.

41. Venkatesan P. Trastuzumab emtansine for HER2-positive breast cancer. Lancet Oncol. 2016; 17:e528.

42. Juntila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, Sampath D, Sliwkowski MX. Ligand-independent HER2/HER3/Pi3K complex is disrupted by trastuzumab and is effectively inhibited by the Pi3K inhibitor GDC-0941. Cancer Cell. 2009; 15:429–40.

43. Orth JD, Krueger EW, Weller SG, McNiven MA. A novel endocytic mechanism of epidermal growth factor receptor
44. Hommelgaard AM, Lerdrup M, van Deurs B. Association with membrane protrusions makes ErbB2 an internalization-resistant receptor. Mol Biol Cell. 2004; 15:1557–67.

45. Miki H, Miura K, Takenawa T. N-WASP, a novel actin-depolymerizing protein, regulates the cortical cytoskeletal rearrangement in a PIP2-dependent manner downstream of tyrosine kinases. EMBO J. 1996; 15:5326–35.

46. Andrianantoandro E, Pollard TD. Mechanism of actin filament turnover by severing and nucleation at different concentrations of ADF/cofilin. Mol Cell. 2006; 24:13–23.

47. Agnew BJ, Minamide LS, Bamburg JR. Reactivation of phosphorylated actin depolymerizing factor and identification of the regulatory site. J Biol Chem. 1995; 270:17582–87.